Argenx (ARGX)
(Real Time Quote from BATS)
$376.23 USD
-3.07 (-0.81%)
Updated Jun 11, 2024 10:30 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
argenex SE [ARGX]
Reports for Purchase
Showing records 21 - 40 ( 280 total )
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Another Setback Offers a Reminder That Drug Development is Hard; Price Target Down to $451
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Vyvgart Fails to Advance in ITP; Price Target Down to $582
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ARGX 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: argenex SE
Industry: Medical - Biomedical and Genetics
As More Look to the FcRn Space, Vyvgart Demonstrates Its Power; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
CHMP Opinion Clears For Efgartigimod SC in Europe
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
SC Efgartigimod Coming Soon to an EU Market Near You
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Efgartigimod Momentum Continues and Starts to Translate to the Rest of the Pipeline; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Upon Vyvgart?s Impressive Results in CIDP, We Raise PT to $595; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D